SeqLL Inc.

General Information

(Note: IPOScoop has No Call on this micro-cap unit offering. Each unit consists of one share of common stock and one warrant to purchase one share of our common stock.)

We are a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields. We intend to leverage our expertise with True Single Molecule Sequencing (“tSMS) technology to enable researchers and clinicians to contribute major advancements to scientific research and development by accelerating one’s understanding of the molecular mechanisms of disease and fundamental biological processes. We believe our proprietary sequencing technology platform has critical advantages over existing Next Generation Sequencing (“NGS”) technologies, particularly for emerging applications in the research and development of biomarker discovery, epigenetics, nucleotide chemistry, forensics, and cell-free nucleic acid analysis. Our mission is to empower researchers with improved genetic tools that enable scientists and physicians to better understand the molecular mechanisms of disease and the underlying biological systems. This knowledge is essential to the continued development of new breakthroughs in genomic medicine that address the critical concerns involved with today’s precision medicine.

Our single molecule technology enables researchers to identify and synthesize DNA or RNA strands, irrespective of abundance, in a biological sample and is capable of analyzing billions of molecules in parallel, which positions us as both competitive and complementary with other NGS platforms. We believe our technology advantage is a simplified method of quantifying DNA and RNA molecules at single molecule resolution because our platform does not require the routine PCR amplification and ligation steps required during library preparation by most NGS systems, thereby avoiding systematic bias and consequential additional costs. Our current sequencing platform offers advantages, such as the ability in certain samples to reveal previously-unknown molecular profiles, by directly detecting single molecules with little to no manipulation of the original sample. Our tSMS platform then generates data that is highly-accurate and creates reproducible molecular profiles, often providing researchers with new insights into the biology being researched. As supported by multiple peer-reviewed research publications, our tSMS technology platform has assisted medical researchers in uncovering potentially significant DNA and RNA biomarkers for the early detection of diseases.

(Note: SeqLL upsized its micro-cap unit offering at pricing on Aug. 26, 2021, to 3.06 million units, up from 2.32 million units, at $4.25 – the low end of its $4.25-to-$5.25 range – to raise $13 million.) 

Employees: 8
Founded: 2014
Contact Information
Address 317 New Boston Street, Suite 210 Woburn, Massachusetts 01801
Phone Number (781) 460-6016
Web Address
View Prospectus: SeqLL Inc.
Financial Information
Market Cap $52.01mil
Revenues $0.33 mil (last 12 months)
Net Income $-2.01 mil (last 12 months)
IPO Profile
Symbol SQL
Exchange NASDAQ
Shares (millions): 3.1
Price range $4.25 - $4.25
Est. $ Volume $13.0 mil
Manager / Joint Managers Maxim Group
CO-Managers -
Expected To Trade: 8/27/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change